ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 013

Kikuchi-Fujimoto’s Disease in Systemic Lupus Erythematosus: Single-center Experience

Areum Shin1, Seonyoung Kang2, Doo Ri Kim2, Soyeon Kim2, Seulkee Lee3, Jaejoon Lee1, Jihyun Kim3, Heeyeon Cho3, Yae-Jean Kim4, Hoon-Suk Cha1 and Kangmo Ahn1, 1Samsung Medical Center, Seoul, 2Samsung Medical Center, Gangnam-gu, Seoul, 3Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, 4Samsung Medical Center, Gangnam District, Seoul

Meeting: 2026 Pediatric Rheumatology Symposium

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Thursday, March 19, 2026

Title: Posters: Clinical and Therapeutic Aspects I

Session Time: 6:00PM-7:00PM

Background/Purpose: Kikuchi-Fujimoto disease (KD), also known as histiocytic necrotizing lymphadenitis, is a self-limited disease of unknown etiology. An association between KD and systemic lupus erythematosus (SLE) has been reported, in which KD diagnosis precedes or follows that of SLE. Dysregulation of type 1 interferon signaling was also observed in lymph node tissues from KD patients. We aimed to explore the clinical characteristics of SLE patients with a preexisting history of KD.

Methods: From 2005 to 2024, patients diagnosed with SLE were identified from electronic medical records. All patients were satisfied with the 2019 EULAR/ACR classification criteria for SLE. Among them, patients with documented KD history in electronic medical records were identified. Patients whose SLE diagnosis predated the KD diagnosis were excluded. Epidemiology and clinical findings, including organ involvement and prognosis, were reviewed.

Results: A total of 1,039 patients with SLE were identified (male: 9.5%). Among them, 37 patients (3.8%) had a preexisting history of KD (male: 8.1%), with a median follow-up of 81 months (IQR: 23-155). For the time interval to SLE following KD diagnosis, nearly 40% of patients (14/37) were diagnosed less than 30 days. The other 23 patients were diagnosed at least 1 month after KD, with a median age at KD diagnosis of 25 years (18-40) and at SLE diagnosis of 31 years (22-45).
Among these 23 patients, seven patients (30.1%) were diagnosed with KD before the age of 19 years old (childhood-onset KD). Their median age at KD diagnosis was 15 years (14-17), and at SLE diagnosis, 17 years (17-21). The median interval to SLE following KD diagnosis was 24 months (10-77), which was longer than the 5 months (1-75) in the adult-onset KD group (16 patients), but the difference was not statistically significant.
Overall, six patients (6/37, 16.2%), including two male patients with childhood-onset KD, presented with neuropsychiatric lupus; of note, all of whom were diagnosed with SLE at least 1 month after KD. Nineteen patients (19/37, 51.4%) presented with lupus nephritis, six patients progressed to chronic kidney disease stage 3 or higher, and two of them developed end-stage renal disease.

Conclusion: The history of KD may be found in a small proportion of newly diagnosed SLE patients. With further studies to analyze the natural course of these patients in detail, guidance on long-term monitoring of childhood-onset KD patients is needed.


Disclosures: A. Shin: None; S. Kang: None; D. Kim: None; S. Kim: None; S. Lee: None; J. Lee: None; J. Kim: None; H. Cho: None; Y. Kim: None; H. Cha: None; K. Ahn: None.

To cite this abstract in AMA style:

Shin A, Kang S, Kim D, Kim S, Lee S, Lee J, Kim J, Cho H, Kim Y, Cha H, Ahn K. Kikuchi-Fujimoto’s Disease in Systemic Lupus Erythematosus: Single-center Experience [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 3). https://acrabstracts.org/abstract/kikuchi-fujimotos-disease-in-systemic-lupus-erythematosus-single-center-experience/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to 2026 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/kikuchi-fujimotos-disease-in-systemic-lupus-erythematosus-single-center-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology